ATE205092T1 - Verfahren zur herstellung hoch-wasserlöslicher zyklodextrinkomplexe - Google Patents

Verfahren zur herstellung hoch-wasserlöslicher zyklodextrinkomplexe

Info

Publication number: ATE205092T1
Authority: AT; Austria
Prior art keywords: optionally substituted; derivative; highly water; soluble cyclodextrin; group
Prior art date: 1992-01-30

Application number

AT93101237T

Other languages

English (en)

Inventor

Yoshihiro Ohmachi

Yoshihiro Tsugawa

Akihiro Nagai

Original Assignee

Takeda Chemical Industries Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-01-30

Filing date

1993-01-28

Publication date

2001-09-15

1993-01-28 Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd

2001-09-15 Application granted granted Critical

2001-09-15 Publication of ATE205092T1 publication Critical patent/ATE205092T1/de

Links

HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 title abstract 6
238000004519 manufacturing process Methods 0.000 title abstract 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title abstract 2
150000003839 salts Chemical class 0.000 abstract 4
150000002284 fumagillol derivatives Chemical class 0.000 abstract 3
229910052739 hydrogen Inorganic materials 0.000 abstract 3
239000001257 hydrogen Substances 0.000 abstract 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
125000000623 heterocyclic group Chemical group 0.000 abstract 2
125000001183 hydrocarbyl group Chemical group 0.000 abstract 2
229910052717 sulfur Chemical group 0.000 abstract 2
125000006020 2-methyl-1-propenyl group Chemical group 0.000 abstract 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
125000002252 acyl group Chemical group 0.000 abstract 1
125000000217 alkyl group Chemical group 0.000 abstract 1
150000001450 anions Chemical class 0.000 abstract 1
239000007864 aqueous solution Substances 0.000 abstract 1
125000003118 aryl group Chemical group 0.000 abstract 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
229910052736 halogen Inorganic materials 0.000 abstract 1
150000002367 halogens Chemical class 0.000 abstract 1
150000002431 hydrogen Chemical class 0.000 abstract 1
238000002347 injection Methods 0.000 abstract 1
239000007924 injection Substances 0.000 abstract 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
229910052757 nitrogen Inorganic materials 0.000 abstract 1
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
229910052760 oxygen Inorganic materials 0.000 abstract 1
239000001301 oxygen Substances 0.000 abstract 1
238000002360 preparation method Methods 0.000 abstract 1
238000003860 storage Methods 0.000 abstract 1
239000000126 substance Substances 0.000 abstract 1
239000011593 sulfur Substances 0.000 abstract 1
125000004434 sulfur atom Chemical group 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Nanotechnology (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Biophysics (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Medical Informatics (AREA)
Molecular Biology (AREA)
Crystallography & Structural Chemistry (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Medicinal Preparation (AREA)

AT93101237T 1992-01-30 1993-01-28 Verfahren zur herstellung hoch-wasserlöslicher zyklodextrinkomplexe ATE205092T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP1523692		1992-01-30
JP33202192		1992-12-11

Publications (1)

Publication Number	Publication Date
ATE205092T1 true ATE205092T1 (de)	2001-09-15

Family

ID=26351355

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT93101237T ATE205092T1 (de)	1992-01-30	1993-01-28	Verfahren zur herstellung hoch-wasserlöslicher zyklodextrinkomplexe

Country Status (5)

Country	Link
US (1)	US5536623A (de)
EP (1)	EP0555693B1 (de)
AT (1)	ATE205092T1 (de)
CA (1)	CA2088428A1 (de)
DE (1)	DE69330690T2 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2210600A1 (en) *	1996-07-17	1998-01-17	Takashi Houkan	Inhibitor of tumor metastasis or recurrence
KR100357541B1 (ko) *	1998-05-15	2002-10-18	주식회사종근당	5-데메톡시 푸마질롤 유도체 및 그 제조방법
KR100357542B1 (ko) *	1998-05-15	2002-10-18	주식회사종근당	푸마질롤 유도체 및 그 제조방법
JP4922507B2 (ja) *	2000-08-10	2012-04-25	武田薬品工業株式会社	医薬組成物
US6951885B2 (en)	2000-08-10	2005-10-04	Takeda Pharmaceutical Company Limited	Pharmaceutical composition
KR100451485B1 (ko) *	2002-03-28	2004-10-06	주식회사종근당	푸마질롤 유도체 또는 그 염의 포접 화합물, 및 이를포함하는 약제학적 조성물
AU2009270799B2 (en) *	2008-07-18	2016-05-19	Zafgen, Inc.	Methods of treating an overweight or obese subject
WO2010065883A2 (en)	2008-12-04	2010-06-10	Zafgen Corporation	Method of treating an overweight or obese subject
WO2010065877A2 (en)	2008-12-04	2010-06-10	Zafgen Corporation	Methods of treating an overweight or obese subject
AU2010303270A1 (en)	2009-10-09	2012-05-03	Zafgen Corporation	Sulphone compounds for use in the treatment of obesity
WO2011085198A1 (en)	2010-01-08	2011-07-14	Zafgen Corporation	Metap-2 inhibitor for use in treating benign prostatic hypertrophy (bph)
AU2011204267B2 (en)	2010-01-08	2015-12-03	Zafgen Corporation	Fumagillol type compounds and methods of making and using same
WO2011127304A2 (en)	2010-04-07	2011-10-13	Zafgen Corporation	Methods of treating an overweight subject
EP2595988B1 (de)	2010-07-22	2014-12-17	Zafgen, Inc.	Tricyclische verbindungen und verfahren zu ihrer herstellung
PH12013500934A1 (en)	2010-11-09	2022-10-24	Zafgen Inc	Crystalline solids of a metap-2 inhibitor and methods of making and using same
AU2011336785A1 (en)	2010-11-29	2013-06-20	Zafgen, Inc	Treatment of obesity using non-daily administration of 6-0-(4 - dimethylaminoethoxy) cinnamoyl fumagillol
BR112013018771A2 (pt)	2011-01-26	2019-09-17	Zafgen Inc	compostos de tetrazol e métodos para fazer e usar os mesmos
BR112013023056A2 (pt)	2011-03-08	2018-10-09	Zafgen Inc	derivados de oxaespiro [2,5] octano e análogos
KR20140040739A (ko)	2011-05-06	2014-04-03	자프겐 인크.	삼환식 피라졸 설폰아마이드 화합물 그리고 그의 제조방법 및 그를 이용하는 방법
AU2012253757B2 (en)	2011-05-06	2017-04-13	Zafgen Inc.	Partially saturated tricyclic compounds and methods of making and using same
WO2012154678A1 (en)	2011-05-06	2012-11-15	Zafgen Corporation	Tricyclic sulfonamide compounds and methods of making and using same
EP2763671A2 (de)	2011-10-03	2014-08-13	Zafgen, Inc.	Verfahren zur behandlung von altersbedingten erkrankungen
EP2804856B1 (de)	2012-01-18	2017-03-15	Zafgen, Inc.	Tricyclische sulfonverbindungen sowie verfahren zur herstellung und verwendung davon
EP2804866B1 (de)	2012-01-18	2016-11-16	Zafgen, Inc.	Tricyclische sulfonamidverbindungen sowie verfahren zur herstellung und verwendung davon
BR112014027808A2 (pt)	2012-05-07	2017-06-27	Zafgen Inc	sal polimórfico do sal de oxalato de 6-o-(4-dimetilaminoetoxi) cinaroil fumagilol e métodos de produção e utilização do mesmo
EP2846792B1 (de)	2012-05-08	2018-08-15	Zafgen, Inc.	Behandlung von hypothalamischer fettsucht mit metap2-inhibitoren
BR112014027981A2 (pt)	2012-05-09	2017-06-27	Zafgen Inc	compostos do tipo fumagilol e métodos de produção e utilização dos mesmos
US9868717B2 (en)	2012-11-05	2018-01-16	Zafgen, Inc.	Tricyclic sulphonamide compounds and methods of making and using same
SG11201503521QA (en)	2012-11-05	2015-06-29	Zafgen Inc	Methods of treating liver diseases
AU2013337282A1 (en)	2012-11-05	2015-05-21	Zafgen, Inc.	Tricyclic compounds and methods of making and using same
MX362391B (es)	2013-03-14	2019-01-15	Zafgen Inc	Métodos de tratamiento de enfermedad renal y otros trastornos.
AR105671A1 (es)	2015-08-11	2017-10-25	Zafgen Inc	Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso
CN106432255A (zh)	2015-08-11	2017-02-22	扎夫根公司	烟曲霉素醇螺环化合物和制备和使用其的方法
CN113321753B (zh) *	2021-05-19	2022-08-30	山东滨州智源生物科技有限公司	多元糖基氨基酸基环糊精衍生物、水凝胶的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH0764884B2 (ja) *	1986-11-27	1995-07-12	株式会社トクヤマ	シクロデキストリン組成物
CA1333363C (en) *	1988-01-19	1994-12-06	Judah Folkman	Angiogenesis inhibitor comprising fumagillin
DE68906942T3 (de) *	1988-03-29	1999-05-12	University Of Florida, Gainesville, Fla.	Pharmazeutische Zusammensetzungen für die parenterale Anwendung.
US5227372A (en) *	1990-03-07	1993-07-13	Children's Medical Center Corporation	Method for retaining ophthalmological agents in ocular tissues
TW282399B (de) *	1990-05-25	1996-08-01	Takeda Pharm Industry Co Ltd
ATE196426T1 (de) *	1991-06-21	2000-10-15	Takeda Chemical Industries Ltd	Zyklodextrin-zusammensetzung enthaltend fumagillol-derivate

1993
- 1993-01-28 AT AT93101237T patent/ATE205092T1/de active
- 1993-01-28 EP EP93101237A patent/EP0555693B1/de not_active Expired - Lifetime
- 1993-01-28 DE DE69330690T patent/DE69330690T2/de not_active Expired - Fee Related
- 1993-01-29 US US08/011,457 patent/US5536623A/en not_active Expired - Fee Related
- 1993-01-29 CA CA002088428A patent/CA2088428A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CA2088428A1 (en)	1993-07-31
EP0555693A1 (de)	1993-08-18
DE69330690T2 (de)	2002-06-20
US5536623A (en)	1996-07-16
DE69330690D1 (de)	2001-10-11
EP0555693B1 (de)	2001-09-05

Publication	Publication Date	Title
ATE205092T1 (de)	2001-09-15	Verfahren zur herstellung hoch-wasserlöslicher zyklodextrinkomplexe
ATE148993T1 (de)	1997-03-15	Zyklodextrinkomplex
ATE71090T1 (de)	1992-01-15	Heterocyclische verbindungen und deren herstellung und verwendung.
JP3673888B2 (ja)	2005-07-20	ポルフィリン類金属錯体の製造方法
ATE145209T1 (de)	1996-11-15	Tri-aza-makrocyclen und verfahren zu ihrer herstellung
KR910004630A (ko)	1991-03-29	4-메틸렌-2-옥소-8-아자스피로[4,5]데칸 유도체들과 그 화합물들을 함유하는 약제학적 조성물 및 그것들을 제조하는 방법
ATE138571T1 (de)	1996-06-15	Verwendung von dioxabicyclo (3.3.0>octane derivaten zur herstellung eines arzneimittels zur hemmung des cholesterinmetabolismus.
DE69013528D1 (de)	1994-12-01	Eine Perfluoralkylgruppe enthaltende Verbindung.
DE60026725D1 (de)	2006-05-11	Verfahren zur herstellung von optisch aktiven naphthalinderivaten und darin eingesetzte optische resolver
DE3885115D1 (de)	1993-12-02	Verfahren zur Herstellung von Thiolen.
ATE122343T1 (de)	1995-05-15	Triazolyl-hydrazidderivate und verfahren zu ihrer herstellung.
RO92245A (ro)	1987-07-30	Procedeu pentru prepararea unor derivati de 1,6-naftiridina
ATE215934T1 (de)	2002-04-15	Neue histidinderivate, verfahren zu ihrer herstellung und ihre verwendung als mittel gegen freie radikale
DE3866148D1 (de)	1991-12-19	Chinolincarbonsaeure-derivate, diese enthaltende zusammensetzung, verfahren zu ihrer herstellung und ihre verwendung zur herstellung von medikamenten.
HU895522D0 (en)	1990-09-28	Process for the preparation of new thienyl-oxy-alkyl-amine derivatives and pharmaceutical compositions containing them
Santos et al.	1993	Siderophore analogues. Chelating properties of a new cyclic diazadihydroxamic acid
ATE7917T1 (de)	1984-06-15	Pyranoindolderivat und verfahren zu seiner herstellung.
SE9802643D0 (sv)	1998-07-29	2,3-Disubstituerade cyklopentanonderivat, förfarande för framställning av den och medicinsk användning därav
KR910006238A (ko)	1991-04-27	피라즐-3-카르복스아미드
AR008257A1 (es)	1999-12-29	Poliamidas estables a la intemperie y procedimiento para su elaboracion y aplicacion
IL106692A (en)	1997-04-15	AZIDOALKYL DERIVATIVES AND THEIR USE FOR THE PREPARATION OF 99mTc COMPLEXES FOR IMAGING
KR880012564A (ko)	1988-11-28	벤즈이미다졸 유도체 및 이의 제조방법
Paradossi et al.	1990	Environmental control of reactions: Influence of poly (glutamate) on the reactivity of cysteine‐quaterpyridineiron (III) mixtures
Le Bozec et al.	1979	Carbon disulphide iron complexes as a source of bis (trifluoroacetato) iron derivatives
ATE228512T1 (de)	2002-12-15	Verfahren zur herstellung von 3-isochromanonen durch cyclisierung von o- chlormehtylphenylessigsäuren